BIOLASE, Inc.

Equities

BIOL

US0909117022

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 08/06/2024 am IST			5-day change	1st Jan Change
0.145 ^USD	-3.27%		-15.11%	-87.08%

14/05	Wall Street Set to Open Flat Tuesday as Key Inflation Gauge Rises More Than Expected	MT
14/05	Top Premarket Decliners	MT

BIOLASE, Inc. Provides Earnings Guidance for the Second Half of 2023

August 11, 2023 at 01:38 am IST

BIOLASE, Inc. provided earnings guidance for the second half of 2023. The company is updating its guidance and now expects revenue for the second half of the year to be 15% to 20% higher than the comparable period a year ago.

Latest news about BIOLASE, Inc.

Wall Street Set to Open Flat Tuesday as Key Inflation Gauge Rises More Than Expected	14/05	MT
Top Premarket Decliners	14/05	MT
BIOLASE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Transcript : BIOLASE, Inc., Q1 2024 Earnings Call, May 13, 2024	14/05
Earnings Flash (BIOL) BIOLASE Posts Q1 Revenue $10.1M, vs. Street Est of $10M	14/05	MT
BIOLASE, Inc. Reiterates Earnings Guidance for the Full-Year of 2024	14/05	CI
Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	01/04	MT
Wall Street Set to Open Marginally Lower Friday Following Powell Speech, After Hitting Record Highs Thursday	22/03	MT
US Stock Futures Flat Ahead of Powell Speech After Reaching Record Highs on Thursday	22/03	MT
Top Premarket Gainers	22/03	MT
Transcript : BIOLASE, Inc., Q4 2023 Earnings Call, Mar 21, 2024	22/03
BIOLASE, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	22/03	CI
BIOLASE, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/03	CI
Biolase Prices $7 Million Public Offering	13/02	MT
BIOLASE, Inc. Provides Earnings Guidance for the Full-Year 2023	30/01	CI
BIOLASE, Inc. Provides Earnings Guidance for the Year 2024	29/01	CI
Dr. Carol Gomez Summerhays Intends to Resign as Member of the Board of Directors of Biolase, Inc	30/12	CI
BIOLASE, Inc. Successfully Concludes Waterlase iPlus All Tissue Laser Trial	13/12	CI
Biolase, Inc. Enters into the Eleventh Amendment to Credit Agreement with SWK Funding LLC	18/11	CI
BIOLASE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Transcript : BIOLASE, Inc., Q3 2023 Earnings Call, Nov 09, 2023	10/11
Earnings Flash (BIOL) BIOLASE Reports Q3 Revenue $10.9M, vs. Street Est of $13.2M	10/11	MT
BIOLASE, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023	10/11	CI
BIOLASE, Inc. Announces Study Performed by the Independent Mcguire Institute Confirms Positive 12 Month Clinical Outcomes for Biolase Repair(R) Perio Protocol	08/11	CI
Biolase Closes Public Offering of 75,000 Units at $60.00 Each	19/23/19	MT

Chart BIOLASE, Inc.

Duration

Period

More charts

Company Profile

BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.

Sector

Advanced Medical Equipment & Technology

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BIOLASE, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.145 USD

Average target price

2.45 USD

Spread / Average Target

+1,589.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIOLASE, INC.	-87.08%	4.84M
THERMO FISHER SCIENTIFIC	+9.48%	222B
DANAHER CORPORATION	+13.72%	195B
INTUITIVE SURGICAL, INC.	+23.79%	148B
BOSTON SCIENTIFIC CORPORATION	+33.39%	113B
SIEMENS HEALTHINEERS AG	+4.75%	66.45B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.16%	50.03B
AGILENT TECHNOLOGIES, INC.	-4.35%	38.8B
GE HEALTHCARE TECHNOLOGIES INC.	-1.27%	34.85B
RESMED, INC.	+22.61%	30.98B

Other Advanced Medical Equipment & Technology